CoChat

The DOI matches its Crossref record; 98 of the 99 references it cites were found in a registry or an index.

Glucagon, from past to present: a century of intensive research and controversies

Scheen, André J, Lefèbvre, Pierre J · 2023 · The Lancet Diabetes & Endocrinology

Abstract

2022 corresponds to the 100th anniversary of the discovery of glucagon. This TimeCapsule aims to recall the main steps leading to the discovery, characterisation, and clinical importance of the so-called second pancreatic hormone. We describe the early historical findings in basic research (ie, discovery, purification, structure, α-cell origin, radioimmunoassay, glucagon gene [GCG], and glucagon receptor [GLR]), in which three future Nobel Prize laureates were actively involved. Considered as an anti-insulin hormone, glucagon was rapidly used to treat insulin-induced hypoglycaemic coma episodes in people with type 1 diabetes. A key step in the story of glucagon was the discovery of its role and the role of α cells in the physiology and pathophysiology (ie, paracrinopathy) of type 2 diabetes. This concept led to the design of different strategies targeting glucagon, among which GLP-1 receptor (GLP1R) agonists were a major breakthrough, and combination of inhibition of glucagon secretion with stimulation of insulin secretion (both in a glucose-dependent manner). Taking advantage of the glucagon-induced increase in energy metabolism, biased coagonists were developed. Besides the GLP-1 receptor, these coagonists also target the glucagon receptor to further promote weight loss. Thus, the 100-year story of glucagon has most probably not come to an end.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(22)00349-7

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 99 references

Cited by

See all 44

Metadata

Authors
Scheen, A. J., & Lefèbvre, P. J.
Affiliations
University of Liège (BE)
Corresponding author
Scheen, André J
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2023-02
Volume
11
Issue
2
Pages
129-138
ISSN
2213-8587 (ISSN-L)
OpenAlex
W4312184764
Cited by
44
References
99
Citations by year
2026: 4 · 2025: 14 · 2024: 16 · 2023: 10
FWCI
2.37
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Open Repository and Bibliography (University of Liège) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
glucagon, glucagon receptor, alpha cells, type 2 diabetes, type 1 diabetes, GLP-1 receptor agonists, glucagon receptor agonist, weight loss, energy metabolism
MeSH terms
Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Glucagon, Humans, Hypoglycemia, Receptors, Glucagon, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon, from past to present: a century of intensive research and controversies. https://app.cochat.ai/papers/10.1016/s2213-8587(22)00349-7
The paper
Scheen, A. J., & Lefèbvre, P. J. (2023). Glucagon, from past to present: a century of intensive research and controversies. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(22)00349-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.